210 related articles for article (PubMed ID: 28263937)
21. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
[TBL] [Abstract][Full Text] [Related]
22. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
[TBL] [Abstract][Full Text] [Related]
23. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation.
Howard PA; Ellerbeck EF; Engelman KK; Patterson KL
Pharmacoepidemiol Drug Saf; 2002; 11(7):569-76. PubMed ID: 12462133
[TBL] [Abstract][Full Text] [Related]
24. Effect of stress on international normalized ratio during warfarin therapy.
Hawk TL; Havrda DE
Ann Pharmacother; 2002 Apr; 36(4):617-20. PubMed ID: 11918508
[TBL] [Abstract][Full Text] [Related]
25. Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Scott KA; Amirehsani KA
J Am Assoc Nurse Pract; 2015 Apr; 27(4):190-6. PubMed ID: 25066647
[TBL] [Abstract][Full Text] [Related]
26. [Has the era of warfarin terminated?].
Pavlova TV; Dupliakov DV; Kuzina TN
Angiol Sosud Khir; 2014; 20(1):16-20. PubMed ID: 24722016
[TBL] [Abstract][Full Text] [Related]
27. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.
Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
Am J Cardiovasc Drugs; 2015 Jun; 15(3):205-11. PubMed ID: 25944648
[TBL] [Abstract][Full Text] [Related]
28. Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.
Ripley TL; Harrison D; Germany RE; Adamson PB
Clin Ther; 2010 Mar; 32(3):506-14. PubMed ID: 20399987
[TBL] [Abstract][Full Text] [Related]
29. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
Koefoed BG; Feddersen C; Gulløv AL; Petersen P
Thromb Haemost; 1997 May; 77(5):845-8. PubMed ID: 9184390
[TBL] [Abstract][Full Text] [Related]
30. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
[TBL] [Abstract][Full Text] [Related]
31. Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
Ząbczyk M; Blombäck M; Majewski J; Karkowski G; Wallen HN; Undas A; He S
Thromb Haemost; 2015 Apr; 113(4):851-61. PubMed ID: 25518887
[TBL] [Abstract][Full Text] [Related]
32. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.
Anthony CJ; Karim S; Ackroyd-Stolarz S; Fry A; Murphy NG; Christie R; Zed PJ
Ann Pharmacother; 2011 Jul; 45(7-8):881-7. PubMed ID: 21750309
[TBL] [Abstract][Full Text] [Related]
33. Use of warfarin in elderly patients with non-valvular atrial fibrillation -- subanalysis of the J-RHYTHM Registry.
Kodani E; Atarashi H; Inoue H; Okumura K; Yamashita T; Origasa H;
Circ J; 2015; 79(11):2345-52. PubMed ID: 26329097
[TBL] [Abstract][Full Text] [Related]
34. High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.
Kim YE; Woo HI; On YK; Kim JS; Lee SY
Eur J Clin Nutr; 2015 Jun; 69(6):703-6. PubMed ID: 25828628
[TBL] [Abstract][Full Text] [Related]
35. [The application of thrombin generation tests to warfarin anticoagulation monitoring].
Chen HY; Ding QL; Zhang LW; Xu GQ; Dai J; Wang XF; Xi XD; Wang HL
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):168-70. PubMed ID: 18788615
[TBL] [Abstract][Full Text] [Related]
36. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
[TBL] [Abstract][Full Text] [Related]
37. Interaction between warfarin and cranberry juice.
Paeng CH; Sprague M; Jackevicius CA
Clin Ther; 2007 Aug; 29(8):1730-5. PubMed ID: 17919554
[TBL] [Abstract][Full Text] [Related]
38. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
[TBL] [Abstract][Full Text] [Related]
39. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY; Frison L; Halperin JL; Lane DA
J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
[TBL] [Abstract][Full Text] [Related]
40. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry.
Subherwal S; Peterson ED; Chen AY; Roe MT; Washam JB; Gage BF; Bach RG; Bhatt DL; Wiviott SD; Lopes RD; Alexander KP; Wang TY
Circulation; 2012 Mar; 125(11):1414-23. PubMed ID: 22319105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
